FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897242856> ?p ?o ?g. }

• W2897242856 endingPage "335" @default.
• W2897242856 startingPage "328" @default.
• W2897242856 abstract "3 classes of biologics are now available for the treatment of Crohn’s disease. The availability of multiple treatment options has led to questions regarding the appropriateness of each agent for a given patient. We aimed to evaluate physician preferences for the use of specific biologic agents in a variety of Crohn’s disease management scenarios using the RAND/UCLA Appropriateness Methodology. A panel consisting of members of the CINERGI group (Canadian IBD Network for Research and Growth in Quality Improvement) was assembled. A literature review was performed on factors identified as influential upon choice of biologic therapy. Clinical scenarios were developed, and panelists rated the appropriateness of biologic therapy classes in each scenario individually and again during a face-to-face meeting after moderated discussion. Two hundred eighty-eight modifications of 3 clinical scenarios were rated. Factors that influenced biologic choice included perianal disease, antidrug antibody status, extraintestinal manifestations, consideration of potential pregnancy, and history of serious infection or malignancy. Anti-TNF therapy was considered appropriate in the postoperative patient. Ustekinumab and vedolizumab were considered appropriate in patients without perianal disease over the age of 65 with a history of malignancy or serious infection. The use of anti-TNF therapy was considered inappropriate in some scenarios whereby drug level was adequate and no antidrug antibody (ADA) was detectable. We evaluated the appropriateness of the 3 available classes of biologics in a number of scenarios for the treatment of Crohn’s disease. History of serious infection and malignancy, particularly in individuals over 65 years, and consideration of future pregnancy were patient-specific variables that impacted treatment decisions. These findings can serve as a guide for providers considering biologic therapy in patients with Crohn’s disease." @default.
• W2897242856 created "2018-10-26" @default.
• W2897242856 creator A5008925096 @default.
• W2897242856 creator A5013202046 @default.
• W2897242856 creator A5018596617 @default.
• W2897242856 creator A5018821861 @default.
• W2897242856 creator A5019773888 @default.
• W2897242856 creator A5027876343 @default.
• W2897242856 creator A5028386079 @default.
• W2897242856 creator A5029894772 @default.
• W2897242856 creator A5054096661 @default.
• W2897242856 creator A5055638169 @default.
• W2897242856 creator A5058310461 @default.
• W2897242856 creator A5058705284 @default.
• W2897242856 creator A5065694547 @default.
• W2897242856 creator A5078207979 @default.
• W2897242856 creator A5083616352 @default.
• W2897242856 creator A5088240942 @default.
• W2897242856 date "2018-10-19" @default.
• W2897242856 modified "2023-10-03" @default.
• W2897242856 title "Appropriateness of Biologics in the Management of Crohn’s Disease Using RAND/UCLA Appropriateness Methodology" @default.
• W2897242856 cites W1955359288 @default.
• W2897242856 cites W1984455842 @default.
• W2897242856 cites W1989167852 @default.
• W2897242856 cites W1991334020 @default.
• W2897242856 cites W1991810959 @default.
• W2897242856 cites W2026116536 @default.
• W2897242856 cites W2067821114 @default.
• W2897242856 cites W2077531651 @default.
• W2897242856 cites W2084215193 @default.
• W2897242856 cites W2090378430 @default.
• W2897242856 cites W2125620933 @default.
• W2897242856 cites W2152029012 @default.
• W2897242856 cites W2161685971 @default.
• W2897242856 cites W2171341132 @default.
• W2897242856 cites W2177651241 @default.
• W2897242856 cites W2316715874 @default.
• W2897242856 cites W2321453230 @default.
• W2897242856 cites W2563487395 @default.
• W2897242856 cites W2569887051 @default.
• W2897242856 cites W2588469439 @default.
• W2897242856 cites W2593531649 @default.
• W2897242856 cites W2603330120 @default.
• W2897242856 cites W2767910653 @default.
• W2897242856 cites W2789263551 @default.
• W2897242856 cites W4233817719 @default.
• W2897242856 doi "https://doi.org/10.1093/ibd/izy333" @default.
• W2897242856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30346529" @default.
• W2897242856 hasPublicationYear "2018" @default.
• W2897242856 type Work @default.
• W2897242856 sameAs 2897242856 @default.
• W2897242856 citedByCount "7" @default.
• W2897242856 countsByYear W28972428562019 @default.
• W2897242856 countsByYear W28972428562020 @default.
• W2897242856 countsByYear W28972428562021 @default.
• W2897242856 countsByYear W28972428562022 @default.
• W2897242856 countsByYear W28972428562023 @default.
• W2897242856 crossrefType "journal-article" @default.
• W2897242856 hasAuthorship W2897242856A5008925096 @default.
• W2897242856 hasAuthorship W2897242856A5013202046 @default.
• W2897242856 hasAuthorship W2897242856A5018596617 @default.
• W2897242856 hasAuthorship W2897242856A5018821861 @default.
• W2897242856 hasAuthorship W2897242856A5019773888 @default.
• W2897242856 hasAuthorship W2897242856A5027876343 @default.
• W2897242856 hasAuthorship W2897242856A5028386079 @default.
• W2897242856 hasAuthorship W2897242856A5029894772 @default.
• W2897242856 hasAuthorship W2897242856A5054096661 @default.
• W2897242856 hasAuthorship W2897242856A5055638169 @default.
• W2897242856 hasAuthorship W2897242856A5058310461 @default.
• W2897242856 hasAuthorship W2897242856A5058705284 @default.
• W2897242856 hasAuthorship W2897242856A5065694547 @default.
• W2897242856 hasAuthorship W2897242856A5078207979 @default.
• W2897242856 hasAuthorship W2897242856A5083616352 @default.
• W2897242856 hasAuthorship W2897242856A5088240942 @default.
• W2897242856 hasBestOaLocation W28972428561 @default.
• W2897242856 hasConcept C126322002 @default.
• W2897242856 hasConcept C177713679 @default.
• W2897242856 hasConcept C2776207728 @default.
• W2897242856 hasConcept C2778260677 @default.
• W2897242856 hasConcept C2778975655 @default.
• W2897242856 hasConcept C2779134260 @default.
• W2897242856 hasConcept C2779280984 @default.
• W2897242856 hasConcept C2779399171 @default.
• W2897242856 hasConcept C2780132546 @default.
• W2897242856 hasConcept C71924100 @default.
• W2897242856 hasConceptScore W2897242856C126322002 @default.
• W2897242856 hasConceptScore W2897242856C177713679 @default.
• W2897242856 hasConceptScore W2897242856C2776207728 @default.
• W2897242856 hasConceptScore W2897242856C2778260677 @default.
• W2897242856 hasConceptScore W2897242856C2778975655 @default.
• W2897242856 hasConceptScore W2897242856C2779134260 @default.
• W2897242856 hasConceptScore W2897242856C2779280984 @default.
• W2897242856 hasConceptScore W2897242856C2779399171 @default.
• W2897242856 hasConceptScore W2897242856C2780132546 @default.
• W2897242856 hasConceptScore W2897242856C71924100 @default.
• W2897242856 hasIssue "2" @default.
• W2897242856 hasLocation W28972428561 @default.
• W2897242856 hasLocation W28972428562 @default.

• next